BCT Overview

Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.

Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.

Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.

Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.

Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.

Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.

Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.

Financial Details: The offering raised a total of US$30 million.

BriaCell Therapeutics' Breakthrough: Shares of BriaCell Therapeutics surged 80% following the announcement of a 100% resolution of lung metastasis in a breast cancer patient treated with their immunotherapy, Bria-OTS, during a Phase 1/2a study.

Positive Clinical Results: The 78-year-old patient, who had previously failed multiple therapies, showed complete resolution of lung tumors after two months of treatment, highlighting the potential of BriaCell's personalized immunotherapy approach.